NCT05563246

A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events

KRAKEN: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Once-Daily LY3473329 in Adults With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 233 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to evaluate the efficacy and safety of LY3473329 in adult participants with elevated Lp(a) at high risk for cardiovascular events.

Conditions

• Lipoprotein Disorder

Interventions

Type	Name	Description
DRUG	LY3473329	Administered orally
DRUG	Placebo	Administered orally

Timeline

• Start date: 2022-11-24
• Primary completion: 2024-03-14
• Completion: 2024-03-14
• First posted: 2022-10-03
• Last updated: 2025-03-25
• Results posted: 2025-03-25

Locations

42 sites across 8 countries: United States, Australia, Brazil, China, Germany, Hungary, Japan, Netherlands

Regulatory

• FDA-regulated drug study